Key focal alterations include CDKN2A/B deletions and high-level EGFR amplifications, which contribute to tumor progression and therapy resistance.116 Recent studies highlight the importance of CNA profiling in stratifying GBM patients and guiding clinical decision-making. The gene discussed is CDKN2A; the disease is glioblastoma.